©The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Urol. Jul 24, 2016; 5(2): 80-89
Published online Jul 24, 2016. doi: 10.5410/wjcu.v5.i2.80
Published online Jul 24, 2016. doi: 10.5410/wjcu.v5.i2.80
Does the molecular classification of breast cancer point the way for biomarker identification in prostate cancer?
William J F Green, Department of Urology, Nottingham City Hospital, Nottingham University Hospitals NHS Trust, Nottingham, NG7 2UH, United Kingom
William J F Green, Graham Ball, Des Powe, the John van Geest Cancer Research Centre, Nottingham Trent University, Nottingham, NG11 8NS, United Kingom
Des Powe, Department of Cellular Pathology, Queen’s Medical Centre, Nottingham University Hospitals NHS Trust, Nottingham NG7 2UH, United Kingom
Author contributions: Green WJF and Powe D contributed equally to this work, both conceptually and in its authorship; Ball G contributed detailed information on bioinfomatic processes and techniques.
Conflict-of-interest statement: All authors declare no conflict of interest.
Correspondence to: Dr. Des Powe, PhD, Department of Cellular Pathology, Queen’s Medical Centre, Nottingham University Hospitals NHS Trust, Derby Road, Nottingham, NG7 2UH, United Kingom. des.powe@nottingham.ac.uk
Telephone: +44-0115-9249924-63484
Received: April 26, 2016
Peer-review started: April 27, 2016
First decision: June 16, 2016
Revised: June 27, 2016
Accepted: July 11, 2016
Article in press: July 13, 2016
Published online: July 24, 2016
Processing time: 89 Days and 18 Hours
Peer-review started: April 27, 2016
First decision: June 16, 2016
Revised: June 27, 2016
Accepted: July 11, 2016
Article in press: July 13, 2016
Published online: July 24, 2016
Processing time: 89 Days and 18 Hours
Core Tip
Core tip: This paper demonstrates that prostate cancer (CaP) has defined molecular subtypes in a similar manner to breast cancer. The molecular classification and subsequent personalised treatment of breast cancer has revolutionised its management. It is becoming increasingly apparent that the same principles may be applied to CaP, allowing more individualised treatment and informing clinical decision making.